ProShare Advisors’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-16,247
| Closed | -$560K | – | 2111 |
|
|
2020
Q3 | $560K | Sell |
16,247
-499
| -3% | -$10.6K | ﹤0.01% | 897 |
|
|
2020
Q2 | $280K | Buy |
16,746
+5,404
| +48% | +$91.8K | ﹤0.01% | 1264 |
|
|
2020
Q1 | $164K | Sell |
11,342
-8,448
| -43% | -$216K | ﹤0.01% | 1033 |
|
|
2019
Q4 | $662K | Sell |
19,790
-2,234
| -10% | -$62.5K | ﹤0.01% | 949 |
|
|
2019
Q3 | $461K | Sell |
22,024
-854
| -4% | -$17.4K | ﹤0.01% | 1008 |
|
|
2019
Q2 | $476K | Sell |
22,878
-3,008
| -12% | -$61.9K | ﹤0.01% | 1037 |
|
|
2019
Q1 | $579K | Buy |
25,886
+269
| +1% | +$6.33K | ﹤0.01% | 970 |
|
|
2018
Q4 | $613K | Sell |
25,617
-3,527
| -12% | -$91.3K | ﹤0.01% | 876 |
|
|
2018
Q3 | $795K | Sell |
29,144
-972
| -3% | -$27.5K | 0.01% | 918 |
|
|
2018
Q2 | $810K | Sell |
30,116
-593
| -2% | -$18.1K | 0.01% | 906 |
|
|
2018
Q1 | $977K | Sell |
30,709
-1,917
| -6% | -$67.5K | 0.01% | 829 |
|
|
2017
Q4 | $1.23M | Buy |
32,626
+1,745
| +6% | +$56.3K | 0.01% | 759 |
|
|
2017
Q3 | $766K | Buy |
30,881
+1,931
| +7% | +$41.6K | 0.01% | 807 |
|
|
2017
Q2 | $595K | Buy |
28,950
+3,303
| +13% | +$63K | 0.01% | 894 |
|
|
2017
Q1 | $557K | Sell |
25,647
-6,575
| -20% | -$135K | 0.01% | 967 |
|
|
2016
Q4 | $659K | Buy |
+32,222
| New | +$659K | 0.01% | 949 |
|
ProShare Advisors's AIMT Position: Q4 2020 in Review
ProShare Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 16,247 shares — an estimated $560K sold.
ProShare Advisors first reported a position in AIMT in Q4 2016 and held it in 16 quarters. The position peaked at $1.23M in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- ProShare Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- ProShare Advisors sold 16,247 Aimmune Therapeutics shares in Q4 2020, an estimated $560K.
- ProShare Advisors first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 16 quarters.
- ProShare Advisors's Aimmune Therapeutics position peaked at $1.23M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on ProShare Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.